Genmab slides as Darzalex combo trials discontinued

Genmab A/S (CSE:GEN; Pink:GMXAY) sank DKK239.30 (20%) to DKK953.20 in Copenhagen on Monday after it said partner Janssen Biotech Inc. will discontinue two studies of Darzalex daratumumab in combination with different immune checkpoint inhibitors.

The studies include the

Read the full 375 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE